TrialPath
Psoriasis · Miami

Psoriasis clinical trials in Miami

8 recruiting psoriasis studies within range of Miami. Click any trial for full eligibility criteria and contact info.

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744 · Juvenile Psoriatic Arthritis
Recruiting

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms. Risankizumab is being studied for the treatment of jPsA and adalimumab is approved for the treatment of jPsA. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to receive adalimumab. Approximately 40 juvenile participants with jPsA will be enrolled at approximately 30 sites worldwide. Participants will receive risankizumab and adalimumab as subcutaneous (SC) injections based on body weight. At the start of Period 1, participants are randomized to receive risankizumab or adalimumab for 24 weeks. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. Those with worsening jPsA symptoms in Period 2 will be withdrawn from the study. Participants who receive adalimumab are followed for safety for 70 days after the last study treatment. Participants who receive risankizumab are followed for 140 days after the last study treatment. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

PhasePhase 3
TypeInterventional
Age5 Years – 17 Years
WhereLittle Rock, Arkansas, United States + 33 more
SponsorAbbVie
▾Tap for details
Apply

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

NCT02418442 · Rheumatic Joint Disease
Recruiting

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

Phase—
TypeObservational
Age21 Years
WhereBirmingham, Alabama, United States + 81 more
SponsorDuke University
▾Tap for details
Apply

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Recruiting

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

PhasePhase 3
TypeInterventional
Age18 Years – 65 Years
WhereGlendale, Arizona, United States + 9 more
SponsorVanda Pharmaceuticals
▾Tap for details
Apply

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702 · Plaque Psoriasis
Recruiting

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

PhasePhase 2
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 38 more
SponsorOruka Therapeutics, Inc.
▾Tap for details
Apply

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453 · Plaque Psoriasis
Recruiting

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

PhasePhase 3
TypeInterventional
Age12 Years – 17 Years
WhereBirmingham, Alabama, United States + 136 more
SponsorBristol-Myers Squibb
▾Tap for details
Apply

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967 · Plaque Psoriasis
Recruiting

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

PhasePhase 3
TypeInterventional
Age40 Years
WhereBirmingham, Alabama, United States + 410 more
SponsorBristol-Myers Squibb
▾Tap for details
Apply

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420 · Palmoplantar Pustulosis
Recruiting

The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).

PhasePhase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 90 more
SponsorUCB Biopharma SRL
▾Tap for details
Apply

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

NCT07286058 · Psoriatic Arthritis
Recruiting

Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD). Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.

PhasePhase 3
TypeInterventional
Age18 Years
WhereTucson, Arizona, United States + 110 more
SponsorTakeda
▾Tap for details
Apply